**Hepatology COVID-19 Registry**  
**Week 16 Report**  
5 new cases added to the report since week 15

<table>
<thead>
<tr>
<th>Gender (%)</th>
<th>Liver disease, Non-Transplant (N=28)</th>
<th>Post-liver transplantation (N=27)</th>
</tr>
</thead>
</table>
|            | Female = 10 (36%)  
Male = 18 (64%) | Female = 14 (51.9 %)  
Male = 13 (48.1 %) |

<table>
<thead>
<tr>
<th>Median Age (yr) at time of COVID diagnosis (range)</th>
<th>8 (0.16-20)</th>
<th>13 (0.5-21)</th>
</tr>
</thead>
</table>

| Etiology of liver disease | Biliary atresia = 7  
NAFLD = 7  
Autoimmune hepatitis = 5  
Acute Liver Failure = 2  
Metabolic disorder = 2  
Others* = 5 | Biliary atresia = 9  
Acute liver failure = 6  
Metabolic disorders = 3  
Tumor = 2  
Others** = 7 |

<table>
<thead>
<tr>
<th>Highest level of care</th>
<th>Outpatient</th>
<th>Hospital floor</th>
<th>ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7</td>
<td>11</td>
<td>10</td>
</tr>
</tbody>
</table>

| Immunosuppression at time of COVID diagnosis | No Immunosuppression = 21  
Azathioprine = 5  
Steroids =3 | Tacrolimus = 23  
Steroids =10  
Mycophenolate Mofetil = 9  
Sirolimus = 3  
Azathioprine = 2  
Cyclosporine =1 |

| Specific Treatment for COVID | Hydroxychloroquine + Azithromycin = 4  
IVIG = 4  
Remdesivir = 4  
Steroids = 3  
Tocilizumab + Sarilumab = 2  
Eculizumab = 2  
Convalescent Plasma = 1  
Anakinra = 1  
Hydroxychloroquine = 1 | Hydroxychloroquine = 2  
Azithromycin = 1  
IVIG = 1  
Favipiravir = 1  
Convalescent Plasma = 2  
Remdesivir = 1  
Steroid (Dexamethasone) = 1 |

<table>
<thead>
<tr>
<th>Highest respiratory support</th>
<th>None</th>
<th>Nasal cannula/CPAP/BiPAP</th>
<th>Mechanical ventilation</th>
<th>High Frequency Oscillatory ventilation</th>
<th>Pending information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Final clinical outcome</th>
<th>Death</th>
<th>Recovery</th>
<th>Still active in clinical course</th>
<th>Pending information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1***</td>
<td>24</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

| Liver related Complications | Ascites = 7  
Portal Hypertension Bleeding =1 | Infection = 1 |
|-----------------------------|---------------------------------|----------------|

*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC
** Others PLT: IFALD, Congenital hepatic fibrosis, AIH-Sclerosing cholangitis, Cryptogenic
***Pulmonary hemorrhage, multi-organ failure

Three recipients had multivisceral transplantation; One PLT recipient also had a transplanted kidney. One had SB+Liver transplant
**Presenting symptoms at time of diagnosis**

*Constitutional symptoms reported: Loss of smell/taste, fever, myalgia, fatigue, sore throat
Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation (MIS-C)*

**Change done to Immunosuppressive agent (Post LT)**

*Stopped, decreased the dose, others and No changes
Commonest agent stopped: Mycophenolate Mofetil*